Clinical Trials Logo

Medullary Thyroid Cancer clinical trials

View clinical trials related to Medullary Thyroid Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04760288 Withdrawn - Clinical trials for Medullary Thyroid Cancer

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

AcceleRET-MTC
Start date: November 30, 2023
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy. Participants will be randomized in a 1:1 ratio into one of two treatment arms: Arm A (pralsetinib) or Arm B (investigator's choice of either cabozantinib or vandetanib for adults and vandetanib for adolescents). Participants whose disease progresses during SOC treatment will be offered the option to cross over to receive pralsetinib after confirmation of progressive disease by blinded independent central review (BICR).

NCT ID: NCT03838692 Withdrawn - Clinical trials for Medullary Thyroid Cancer

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Start date: July 26, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine in an exploratory manner the objective overall response rate to ponatinib in the treatment of patients with advanced or metastatic MTC previously treated with cabozantinib or vandetanib who have tumors with rearranged-during-transfection (RET) mutations and have tumors without RET mutations.